Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY23 results · Jul–Sep 2022
Procter & Gamble Health reported revenue from operations of ₹297.55 crore (up 9.1% from Q2 FY22) and net profit of ₹63.66 crore (up 15.0% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 297.55 | 272.80 | +9.1% | 295.89 | +0.6% |
| Other income | 3.42 | 3.04 | +12.5% | 3.10 | +10.3% |
| Total income | 300.97 | 275.84 | +9.1% | 298.99 | +0.7% |
| Profit before tax | 86.60 | 74.07 | +16.9% | 54.65 | +58.5% |
| Net profit for the period | 63.66 | 55.37 | +15.0% | 41.19 | +54.6% |
| EPS, basic (₹) | 38.30 | 33.40 | not comparable | 24.80 | +54.4% |
| Net margin (%) | 21.4 | 20.3 | 13.9 |
Standalone
- Filed with BSE
- 13 Nov 2022, 12:51 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE